“Bimekizumab 4-Year Maintenance of Responses in Week 16 Responders With Moderate to Severe Plaque Psoriasis: Results from the BE BRIGHT Open-Label Extension Phase 3 Trial”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 6, Nov. 2024, p. s437, https://doi.org/10.25251/skin.8.supp.437.